Valuation: Healios K.K.

Market Cap 34.56B 213M 186M 172M 158M 298M 20.49B 305M 2.04B 806M 10.03B 799M 781M P/E 2026 *
-7.03x
P/E 2027 * -12.5x
Enterprise Value 34.3B 211M 185M 171M 157M 296M 20.33B 303M 2.02B 800M 9.95B 793M 775M EV / Sales 2026 *
57x
EV / Sales 2027 * 3.95x
Free-Float
77.9%
Yield 2026 *
-
Yield 2027 * -
1 day-4.12%
1 week-1.92%
Current month+1.19%
1 month-3.76%
3 months-30.81%
6 months-20.00%
Current year-6.57%
1 week 249
Extreme 249
285
1 month 235
Extreme 235
285
Current year 234
Extreme 234
483
1 year 234
Extreme 234
747
3 years 114
Extreme 114
747
5 years 114
Extreme 114
2,557
10 years 114
Extreme 114
2,557
Manager TitleAgeSince
Chief Executive Officer 49 2018-02-28
Director of Finance/CFO 49 2019-07-15
Chief Tech/Sci/R&D Officer - 2025-12-31
Director TitleAgeSince
Director/Board Member 49 2012-01-31
Director/Board Member 49 2018-02-28
Director/Board Member 72 2018-02-28
Change 5-day change 1-year change 3-year change Capi.($)
-4.12%-1.92%-63.43%-14.95% 213M
+0.24%-1.54%+52.85%+71.85% 53.83B
-7.17%-4.39%+42.72%+73.32% 52.1B
+0.80%-6.31%+5.62%+417.78% 23.48B
-0.09%-0.01%-16.85%-15.41% 23.13B
-5.95%-2.58%+29.53%-9.47% 19.36B
-1.14%+0.03%+31.67%-30.65% 17.56B
-5.16%-7.00%+168.44%+314.96% 15.2B
-6.91%-5.83%+25.17%+644.30% 14.83B
+0.43%-1.03%+25.75%+189.74% 14.06B
Average -2.91%-2.55%+30.15%+164.15% 23.38B
Weighted average by Cap. -2.80%-2.36%+39.45%+142.98%

Financials

2026 *2027 *
Net sales 602M 3.7M 3.24M 3M 2.76M 5.19M 357M 5.31M 35.55M 14.04M 175M 13.92M 13.61M 9.12B 56.08M 49.1M 45.37M 41.74M 78.61M 5.4B 80.43M 538M 213M 2.65B 211M 206M
Net income -4.77B -29.34M -25.69M -23.74M -21.84M -41.13M -2.83B -42.08M -282M -111M -1.38B -110M -108M -2.94B -18.11M -15.86M -14.65M -13.48M -25.39M -1.75B -25.97M -174M -68.67M -854M -68.05M -66.56M
Net Debt -260M -1.6M -1.4M -1.29M -1.19M -2.24M -154M -2.29M -15.34M -6.06M -75.36M -6M -5.87M 1.46B 9M 7.88M 7.28M 6.7M 12.61M 867M 12.9M 86.36M 34.12M 424M 33.81M 33.07M
Logo Healios K.K.
Healios KK is a Japan-based company mainly engaged in business in the somatic stem cell regenerative medicine field and in the iPSC regenerative medicine field, which involves research, development and manufacture of regenerative medicine products (iPSC regenerative medicines) utilizing technologies related to induced pluripotent stem cells (iPS cells, iPSCs). The somatic stem cell regenerative medicine field develops and markets cell therapy drugs for acute stroke and acute respiratory distress syndrome using MultiStem, a somatic stem cell product for which the Company holds patent and patent licensing rights. The iPSC regenerative medicines include the creation of universal donor cells (UD), next-generation iPSCs that reduce the risk of immune rejection regardless of human leukocyte antigen (HLA) type using gene editing technology.
Employees
75
Date Price Change Volume
26-07-17 JP¥256.00 -4.12% 1,849,300
26-07-16 JP¥267.00 -4.64% 1,600,300
26-07-15 JP¥280.00 +7.28% 1,898,200
26-07-14 JP¥261.00 -1.14% 847,300
26-07-13 JP¥264.00 +1.15% 1,229,000
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
256.00JPY
Average target price
779.83JPY
Spread / Average Target
+204.62%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 4593 Stock